JSKN003 is an anti-HER2 bispecific ADC developed inhouse with Alphamab's proprietary Glycan-specific conjugation platform. The antibody molecule KN026 is site-specifically modified via enzyme ...

Under the terms of the Exclusive License, Radiance will pay CSPC an upfront payment of $15 million, and up to $150 million in potential development and regulatory milestone payments and over $1 ...

Alphamab Oncology has dosed the first subject in the randomised Phase III JSKN003-306 trial of its anti-human epidermal ...

More than 13 years after its initial FDA approval, Pfizer’s blood cancer drug Adcetris has nabbed another regulatory green ...

JSKN003 is an anti-HER2 biparatopic ADC, which is developed inhouse with Alphamab's proprietary Glycan-specific conjugation platform. Compared with its ADC counterparts, JSKN003 demonstrated better ...

ADC Therapeutics SA (NYSE ... trial evaluating the safety and efficacy of ZYNLONTA® in combination with the bispecific antibody glofitamab (COLUMVI™) in patients with relapsed or refractory ...

JSKN003 is an anti-HER2 bispecific ADC developed inhouse with Alphamab's proprietary Glycan-specific conjugation platform. The antibody molecule KN026 is site-specifically modified via enzyme ...

Radiance's current oncology pipeline includes RB-201, a bispecific HER2xTROP2 ADC for solid tumors. For more information on Radiance visit www.radiancebiopharma.com. CSPC is a leading ...